Marina Biotech, Inc.  

(Public, OTCMKTS:MRNA)   Watch this stock  
Find more results for NASDAQ:MRNA
0.960
-0.040 (-4.00%)
Sep 19 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.94 - 1.01
52 week 0.19 - 1.81
Open 0.94
Vol / Avg. 27,778.00/189,255.00
Mkt cap 24.61M
P/E     -
Div/yield     -
EPS -2.62
Shares 25.63M
Beta -0.30
Inst. own 1%
Sep 10, 2014
Marina Biotech Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -158.23% -1315.92%
Operating margin -144.57% -1565.07%
EBITD margin - -729.87%
Return on average assets -77.14% -142.86%
Return on average equity - -342.00%
Employees 11 -
CDP Score - -

Address

3830 Monte Villa Parkway
BOTHELL, WA 98021
United States - Map
+1-425-9083600 (Phone)
+1-302-6555049 (Fax)

Website links

Description

Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation. The Company's pipeline includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in bladder cancer and myotonic dystrophy. The Company has two liposomal-based delivery platforms. The first platform utilizes amino-based liposomal delivery technology and incorporates a molecule the Company calls DiLA2 (Di-Alkylated Amino Acid). In April 2012, the Company announced the completion of dosing for Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial of CEQ508.

Officers and directors

J. Michael French Chairman of the Board, President, Chief Executive Officer
Age: 53
Daniel E. Geffken Interim Chief Financial Officer
Age: 57
Stefan D Loren Ph.D. Lead Independent Director
Age: 48
Philip C. Ranker Director
Age: 53
Trading Activity - Yahoo Finance
Joseph W. Ramelli Independent Director
Age: 44